Research Article
Correlation between the Immune Checkpoint Inhibitors Prognostic Index and Outcomes in Nonsmall Cell Lung Cancer: A Multicentre Analysis
Table 1
The baseline characteristics of the ICIs cohort.
| | Patients (n = 143) |
| | Sex | | Male | 119 (83.2) |
| | Age (year) | | ≥65 | 57 (39.9) |
| | Smoking status | | Nonsmoker | 37 (25.9) | | Smoker | 106 (74.1) |
| | Histology | | Adenocarcinoma | 73 (51.0) | | Squamous | 61 (42.7) | | NSCLC-others | 9 (6.3) |
| | KRAS alteration status | | KRAS wild-type | 65 (45.5) | | KRAS mutant | 6 (4.2) | | NA | 72 (50.3) |
| | PD-L1 status | | Negative | 8 (5.6) | | Positive | 24 (16.8) | | NA | 111 (77.6) |
| | PS (ECOG) | | 0-1 | 141 (98.6) | | ≥2 | 2 (1.4) |
| | Stage | | I-II | 7 (4.9) | | IIIA | 9 (6.3) | | IIIB–IV | 127 (88.8) |
| | Metastatic sites number | | <2 | 57 (39.9) | | ≥2 | 86 (60.1) |
| | Metastatic sites | | Live | 18 (12.6) | | Bone | 34 (23.8) | | Brain | 19 (13.3) | | WBC (×109/L) | 6.62 (5.51–8.87) | | ANC (×109/L) | 4.36 (3.09–6.01) | | ALC (×109/L) | 1.46 (1.02–1.82) | | MON (×109/L) | 0.59 (0.42–0.81) | | RDW (%) | 13.8 (13.1–15.0) | | PLT (×109/L) | 230 (174–296) | | ALB (g/L) | 40.89 ± 4.85 | | PLR | 155.62 (117.56–227.74) | | dNLR | 2.08 (1.45–2.74) |
| | ICIs drug | | Sintilimab | 20 (14.0) | | Nivolumab | 37 (25.9) | | Pembrolizumab | 86 (60.1) |
| | ICIs treatment modality | | ICI monotherapy | 46 (32.2) | | ICI + chemotherapy | 87 (60.8) | | ICI + antiangiogenic | 10 (7) |
| | ICIs line | | 1 | 46 (32.2) | | ≥2 | 97 (67.8) |
| | Previous treatments before ICIs | | Chemotherapy | 89 (62.2) | | Radiotherapy | 23 (16.1) | | EGFR-TKI | 12 (8.4) | | Antiangiogenic | 25 (17.5) | | Surgery | 13 (9.1) |
| | Disease response | | CR | 2 (1.4) | | PR | 60 (42.0) | | SD | 55 (38.5) | | PD | 26 (18.2) |
| | Response rates | | ORR (%) | 43.4 | | DCR (%) | 81.8 |
|
|
NA, not assessable; MON, monocyte.
|
